Form 4: Tarsus Pharmaceuticals COO Receives Stock Options and Restricted Stock Units

Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units on March 5, 2025.

Summary

• On March 5, 2025, Seshadri Neervannan, the Chief Operating Officer of Tarsus Pharmaceuticals, received stock options and restricted stock units (RSUs).
• The stock options grant consists of 30,628 shares with an exercise price of $44.54.
• These options vest over four years, starting March 5, 2026, with 25% vesting initially and the remainder vesting monthly over the subsequent three years, contingent upon continuous service.
• Neervannan also received 20,089 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects mentioned.

Positives

• The grant of stock options and RSUs aligns the COO's interests with those of the shareholders, incentivizing him to drive company growth.
• The vesting schedules encourage long-term commitment and retention of the COO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Tarsus Pharmaceuticals' stock price.
• If the stock price does not appreciate, the options may not be valuable to the COO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the pharmaceutical industry to incentivize performance and retain talent. This aligns executive compensation with shareholder value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the pharmaceutical industry.
• Companies like Amgen, Regeneron, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and grant sizes are generally comparable to industry benchmarks for similar roles and company sizes.

Stakeholder Impact

• Shareholders may view the grant positively as it incentivizes the COO to improve company performance.
• Employees may see it as a sign of confidence in the company's future.

Key Dates